8:00 am Check-In Opens & Morning Welcome Coffee & Light Breakfast

8:40 am Chair’s Opening Remarks

  • Andrew Allen President & Chief Executive Officer, Gritstone Bio

Exploring Novel Prediction Strategies & Targets to Improve Immunogenic Effects Leading to More Effective Neoantigen Therapies

8:50 am Building High-Performance Off-the-shelf Therapeutic Vaccines Based on Shared TSAs from the Cryptic Genome

  • Jon Moore Chief Scientific Officer & Co-Founder, Epitopea


  • Epitopea is exploiting a new family of mass spec identified wild-type TSAs derived from so-called non-coding DNA that represent the major opportunity for T cell-mediated control of tumours
  • Configured into a LNP-mRNA vaccine, the mouse counterparts of these antigens control tumour growth as single agents
  • We are configuring human cryptic TSAs into highly effective cancer vaccines, where each class I TSAs within can be confirmed to be presented by mass spectroscopy

9:20 am Personalized T-cell Therapy for Solid Tumours: Novel Platforms to Create Patient-Specific TCR Therapies Targeting Neoantigens


  • Uncovering NEOXpress Platform to identify, clone and express neoantigens for personalized therapies
  • Highlighting TCXpress platform to identify effective neoantigen targeting TCRs
  • Showcasing a quick and cost effective process to produce TCR therapies against neoantigens

9:50 am Detecting New Mutation Targets for Developing Effective Personalised Cancer-Immuno-Therapies


  • Creating bioinformatic tools to detect new potential targets for personalised therapies
  • Evaluating the response caused by these new neoantigens
  • Using AI and machine learning to improve the success rate of target detection

10:20 am First-In-Class Inhibitors of ERAP1 Generate Novel Targets for MHC-IDirected Therapies

  • Wayne Paes Senior Scientist, Grey Wolf Therapeutics


  • Inhibition of ERAP1 by first-in-class small molecule inhibitors significantly alters the antigenic repertoire of cancer cells
  • Novel ERAP1-independent epitopes are presented on MHC-I molecules for immune recognition
  • Cytotoxic T cell recognition of these novel epitopes mediates tumor cell lysis

10:50 am BCN Peptides: Cutting-Edge Technology for the Manufacturing of Personalized Neoantigen Peptide Therapies


  • BCN Peptides is a European privately held company focused on the GMP industrial manufacture of bioactive peptides. Our Peptide-based Personalized Medicine Laboratory (PPM Lab) has been designed and equipped with state-of-the-art technology
  • Our software enables full GMP control through online management of sequences, real-time process monitoring, and automatized revision and CoA issuance
  • Peptide-based anticancer vaccination has proven the ability to induce cancer-specific immune responses and allows the production of safe and effective individualized neoantigen peptide therapies

11:00 am Morning Break & Speed Networking


This session is your opportunity to get face-to-face with many of the brightest minds working in the Neoantigen field, and establish meaningful business relationships to pursue for the rest of the conference

Driving More Successful Approvals by Leveraging Clinical Data & Investment Insights to to Fast-track Therapies to Patients

12:00 pm Fireside Chat: Discussing Investment Opportunities for Better Understanding of What Venture Capitalists are Looking for to Enable Advancement of Neoantigen Therapies


  • What are the risk factors that investors are concerned about causing them to withold?
  • How to develop the most effective data packages for investors?
  • How do investors view neoantigen companies?

12:30 pm Clinical Trial Data with a Personalized Neoantigen Cancer Vaccine in Metastatic Colorectal Cancer

  • Andrew Allen President & Chief Executive Officer, Gritstone Bio


  • We have developed a heterologous prime-boost personalized neoantigen cancer vaccine using adenoviral prime and self-amp mRNA boost vectors
  • Phase 1 data demonstrated good safety, immunogenicity and early signals of clinical benefit
  • A randomized, controlled phase 2 trial in metastatic colorectal cancer is expected to report preliminary data from a subset of patients in 1 Q24

1:00 pm Uncovering an Off-the-shelf Peptide-Based Cancer Vaccine

  • Eniko Toke Chief Scientific Officer, Treos Bio Inc.


  • Highlighting a novel platform used which takes into account the tumour heterogeneity as well as patient heterogeneity
  • Evaluating clinical trials which took place in the most difficult-to-treat colorectal cancer (MSS mCRC)
  • Showcasing correlation studies for the identification of a candidate predictive biomarker

1:30 pm Accelerating Personalized Peptide Vaccine Trials


  • What are current challenges when conducting trials on personalized peptide vaccines?
  • How do you choose the right CDMO to meet those challenges?

1:40 pm Lunch & Networking

Spotlighting Personalised Medicines & Navigating Challenges of Time & Cost to Improve Feasibility of Advanced Cancer Treatments

2:30 pm Building a High Throughput Manufacturing Facility for Personalised Vaccines


  • Key considerations for High Throughput manufacturing
  • Technical, quality and regulatory considerations
  • Future directions

2:40 pm Roundtable Discussion: Discussing Strategies to Reduce Turnaround Time & Improve CostEffectiveness for More Successful Translation into the Clinic


  • Which stage of production does the field need to focus on improving to accelerate the turnaround time?
  • What strategies are the field currently implementing to improve the cost restraints of personalised medicines?
  • Are there novel manufacturing methods which can be used to reduce turnaround time?

3:40 pm Afternoon Networking Break & Scientific Poster Session

4:10 pm Personalized DNA Neoantigen Vaccine & Pembrolizumab in Advanced Hepatocellular Carcinoma

  • Jian Yan Vice President - Research & Discovery, Geneos Therapeutics


  • Updates on clinical response data from GNOS-PV02 Phase 1b/2a clinical trial in 2L advanced HCC
  • Highlighting pharmacodynamic and biomarker data from personalized DNA cancer vaccine in combination with Pembrolizumab
  • What are critical factors for clinical translation of personalized therapies?

4:40 pm Personalis: Best-in-Class NGS Partner for Individualised Neoantigen-based Therapy Design and Response Monitoring

  • Nancy Groot Director - Biopharma Business Development, Personalis


  • ImmunoID NeXT; multidimensional view of the tumour and the TME from a single sample, including comprehensive neoantigen identification (with accelerated TATs)
  • NeXT Personal; ultra-sensitive, tumour-informed liquid biopsy assay for MRD detection and therapy response monitoring, with simultaneous variant tracking

4:50 pm GoldspireTM Personalized Tumour-Derived Late Stage Clinical Immunotherapy Platform Uses the Full Antigenic Signature of Solid Tumour to Induce Durable Anti-Tumour Immunity


  • Goldspire personalized tumour-derived immunotherapy is safe and clinically active in glioblastoma
  • Goldspire is active in multiple solid tumour preclinically, induces durable systemic anti-tumour immunity
  • Goldspire is currently in late stage clinical development in glioblastoma

5:20 pm Chair’s Closing Remarks & End of Conference Day One

  • Andrew Allen President & Chief Executive Officer, Gritstone Bio